With U.S. recommendations for COVID-19 vaccines in flux, a leading member of the CDC's COVID vaccine advisory group is ...

Novartis admitted the email broke several rules set out in the U.K. marketing code. In a long response to the PMCPA, the ...

Antheia, a biomanufacturer that makes a key ingredient for the opioid overdose treatment Narcan, reeled in $56 million in a ...

Bayer has taken another step toward achieving its €3 billion peak sales estimate for androgen receptor inhibitor Nubeqa, ...

Almost exactly a year after launching its Obesity Association, the American Diabetes Association (ADA) has recruited Novo ...

With those findings in mind, the ABPI recommended in the report that pharmas “explore the appropriate use of social media ...

With the American Society of Clinical Oncology (ASCO) annual meeting in full swing at Chicago’s McCormick Place this past ...

With the deal, Sanofi gains Blueprint’s portfolio of rare immunological disease treatments, including systemic mastocytosis ...

Despite its success in advanced melanoma, Bristol Myers Squibb’s fixed-dose PD-1/LAG-3 combo, Opdualag, failed to move the ...

Agenus, which has been going through a reorganization after the FDA put the brakes on the biotech's regulatory plan for its ...

Though they are both multiple myeloma drugs with the same mechanism of action, Sanofi’s Sarclisa has had difficulty competing ...

The FDA has already approved PARP inhibitors in certain patients with metastatic castration-resistant prostate cancer (mCRPC) ...